Pfizer

Page 2 of 37

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Commentary

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

By Jeffrey Sonnenfeld and Steven Tian
February 5, 2025
Albert Bourla, chief executive officer of Pfizer Inc., during a panel session at the World Economic Forum
Health

Pfizer CEO had dinner with RFK Jr.: ‘I’m cautiously optimistic’ in spite of his history with vaccines

By
February 4, 2025
Row of medical vials and syringe
Health

Pfizer’s Covid boost overshadowed by Kennedy threat to vaccines

By Bloomberg and Damian Garde
February 4, 2025
Pfizer (PFE) Q4 2024 Earnings Call Transcript

Pfizer (PFE) Q4 2024 Earnings Call Transcript

By
February 4, 2025
Days before President Donald Trump took office a second time, the Department of Health and Human Services granted Moderna $590 million for the development of mRNA vaccines for bird flu and other influenza viruses.
Health

As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines

By
January 23, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By
January 22, 2025
A white sign featuring the Pfizer logo
Health

GSK, Pfizer RSV shots must warn about rare paralysis risk

By
January 8, 2025
Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1
Health

Pfizer has increased prices on over 60 drugs in the U.S. as of Jan. 1

By
January 3, 2025
As activist Starboard engages constructively, here’s a potent prescription for Pfizer’s future success under Dr. Bourla’s watch
Commentary

As activist Starboard engages constructively, here’s a potent prescription for Pfizer’s future success under Dr. Bourla’s watch

By Jeffrey Sonnenfeld and Steven Tian
October 24, 2024
Just 25% of people at high risk of pneumococcal disease—children younger than 2, adults older than 64, and those with certain chronic health conditions such as diabetes—have been immunized, according to an August 2024 survey by the National Foundation for Infectious Diseases.
Health

Pneumonia can be a deadly complication of COVID, the flu, and RSV: What to know about pneumococcal vaccination

By
October 22, 2024
Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis
Commentary

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

By Jeffrey Sonnenfeld and Steven Tian
October 10, 2024
Albert Bourla puts his palm flat on tup of his other hand, rolled up in a fist, as he sits and listens to a question onstage at a conference.
Finance

Pfizer stock surges 3% after activist Starboard takes $1 billion stake, taps former execs

By
October 7, 2024
As of spring 2024, at which time two RSV vaccines had been FDA-approved, less than 25% of eligible U.S. adults 60 and older had gotten one, according to the CDC.

RSV can be deadly, especially for older adults. What to know about symptoms and the new vaccine

By
October 4, 2024
About 47% of U.S. adults aged 50 and older said they were very or somewhat unlikely to get the new 2024–25 COVID-19 vaccine, according the University of Michigan’s National Poll on Healthy Aging.
Health

COVID sickens older adults most severely, but less than half say they’ll get the new vaccine

By
September 30, 2024

Most Popular